Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Trends: Insider Disposition Eases Back 90-Day Buy Trend at Antares Pharma

07/09/2021 | 05:11pm EDT


© MT Newswires 2021
All news about ANTARES PHARMA, INC.
09/08ANTARES PHARMA : to Participate in the H.C. Wainright 23rd Annual Global Investm..
PU
09/08Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Inves..
GL
08/18ANTARES PHARMA, INC. : Regulation FD Disclosure (form 8-K)
AQ
08/06Antares pharma reports second quarter 2021 financial and operating resultsewi..
AQ
08/05ANTARES PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
08/05ANTARES PHARMA, INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/05Antares Pharma, Inc. Reaffirms Revenue Guidance for the Full Year 2021
CI
08/05ANTARES PHARMA : Q2 Earnings Snapshot
AQ
08/05ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Reports Q2 Revenue $45M, v..
MT
08/05ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Posts Q2 EPS $0.03, vs. St..
MT
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 188 M - -
Net income 2021 18,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 34,5x
Yield 2021 -
Capitalization 620 M 620 M -
Capi. / Sales 2021 3,30x
Capi. / Sales 2022 2,66x
Nbr of Employees 185
Free-Float 97,9%
Chart ANTARES PHARMA, INC.
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | ATRS | US0366421065 | MarketScreener
Technical analysis trends ANTARES PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,65 $
Average target price 6,64 $
Spread / Average Target 82,0%
EPS Revisions
Managers and Directors
Robert F. Apple President, Chief Executive Officer & Director
Fred M. Powell Chief Financial Officer & Executive Vice President
Leonard S. Jacob Chairman
Jonathan S. Jaffe Vice President-Clinical & Medical Affairs
Peter C. Richardson Chief Medical Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
ANTARES PHARMA, INC.-8.52%620
ABBOTT LABORATORIES16.44%226 016
MEDTRONIC PLC12.39%177 176
BECTON, DICKINSON AND COMPANY4.58%75 152
HOYA CORPORATION33.15%63 447
SARTORIUS STEDIM BIOTECH82.07%57 757